This article was originally published in Pharmaceutical Approvals Monthly
Approvable" letter issued June 2 for combination of Xalatan (latanoprost) and beta blocker timolol (Merck's Timoptic) to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta blockers, prostaglandins or other IOP-lowering medications. The application is receiving priority review. Pharmacia's Xalatan is indicated for open-angle glaucoma and ocular hypertensio
You may also be interested in...
The American Telemedicine Association backed use of more telehealth providers and changes to remote monitoring reimbursements in comments to the US Medicare agency.
STADA Strengthens Specialty Partnership Role Via US Filing
Textualist judges appointed by President Trump during his term may block a potential President Biden’s attempts to shift the government’s legal policies, experts tell Medtech Insight.